<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651584</url>
  </required_header>
  <id_info>
    <org_study_id>HS-11-421</org_study_id>
    <nct_id>NCT02651584</nct_id>
  </id_info>
  <brief_title>Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel Group, Multi-center Trial Assessing the Efficacy and Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Treatment of Adult Outpatients With Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braeburn Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braeburn Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group
      multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an
      existing standard of care (SL BPN/NX) in initiation and maintenance treatment with BPN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, randomized, double-blind, double-dummy, active-controlled, parallel
      group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an
      existing standard of care (SL BPN/NX) in initiation and maintenance treatment with BPN. The
      trial will involve 4 phases: Screening, Phase 1 (weekly visits), Phase 2 (monthly visits),
      and Follow-up.

      Approximately 380 subjects (190 subjects per arm) will be randomized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate, Denoted by Response Rate (Weeks 1-24).</measure>
    <time_frame>24 weeks</time_frame>
    <description>Response Rate, denoted by response rate (Weeks 1-24). A responder is defined as a subject with at least 33% of urine toxicology results collected during the Phase 1 (4 out of 12 urine samples) and 67% of urine toxicology results collected during Phase 2 (4 out of 6 urine samples) being negative for illicit opioids and self - reported illicit opioid use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Distribution Function (CDF) of Percentage of Urine Samples Negative for Illicit Opioids</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cumulative distribution function (CDF) of percentage of urine samples negative for illicit opioids comparing CAM2038 to SL BPN/NX as (supported by self-reported opioid use results)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Sustained Abstinence of Opioid Use</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of Subjects with Sustained Abstinence of Opioid Use taking SL BPN/NX and CAM2038</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Remaining in the Study (Retention Rate)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of Subjects Remaining in the Study (Retention Rate) on SL BPN/NX and CAM2038</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">428</enrollment>
  <condition>Opioid Use Disorders</condition>
  <arm_group>
    <arm_group_label>SL BPN/NX tabs + placebo SC injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAM2038 SC injections + SL placebo tabs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 or 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM2038 SC injection</intervention_name>
    <arm_group_label>CAM2038 SC injections + SL placebo tabs</arm_group_label>
    <other_name>Buprenorphine injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL BPN/NX tabs</intervention_name>
    <arm_group_label>SL BPN/NX tabs + placebo SC injections</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo SC injections</intervention_name>
    <arm_group_label>SL BPN/NX tabs + placebo SC injections</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL placebo tablets</intervention_name>
    <arm_group_label>CAM2038 SC injections + SL placebo tabs</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must provide written informed consent prior to the conduct of any
             trial-related procedures.

          2. Male or female, 18-65 years of age, inclusive.

          3. Diagnosis of moderate or severe opioid use disorder as described (DSM-V).

          4. Voluntarily seeking treatment for opioid use disorder.

          5. Have not received medication-assisted treatment for opioid use disorder within 60 days
             prior to randomization.

          6. Considered by the Investigator to be a good candidate for BPN treatment, based on
             medical and psychosocial history.

          7. Male or Female subjects of childbearing potential must be willing to use a reliable
             method of contraception during the entire trial (Screening visit to Follow-up visit)

        Exclusion Criteria:

          1. Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS).

          2. Current diagnosis of chronic pain requiring opioids for treatment.

          3. Current DSM-V diagnosis of moderate to severe substance use disorder on any other
             psychoactive substances other than opioids, caffeine or nicotine (e.g., alcohol,
             cocaine, sedatives).

          4. Pregnant or lactating or planning to become pregnant during the trial.

          5. Hypersensitivity or allergy to BPN or other opioids, naloxone or other opioid
             antagonists, or excipients of CAM2038 or SL BPN.

          6. Requires current use of agents that are strong inhibitors or inducers of cytochrome
             P450 3A4 (CYP3A4) such as some azole antifungals (e.g., ketoconazole), macrolide
             antibiotics (e.g., clarithromycin), or protease inhibitors (e.g., ritonavir,
             indinavir, and saquinavir).

          7. Subjects with active signs or symptoms of hepatitis and requiring treatment. Subjects
             with no acute signs of inflammation, and no clinical necessity for therapy will be
             allowed, at the discretion of the Investigator.

          8. Recent history of or current evidence of suicidal ideation or active suicidal behavior
             as based on the Columbia Suicide Severity Rating Scale (C-SSRS) (&quot;Yes&quot; responses to
             questions 4 or 5).

          9. Any pending legal action that could prohibit participation or compliance in the trial.

         10. Exposure to any investigational drug within the 4 weeks prior to Screening.

         11. Participants with a history of risk factors of Torsades de Pointes (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome) or an electrocardiogram
             (ECG) demonstrating a Fridericia's corrected QT interval (QTcF) &gt;450 msec in males and
             QTcF &gt;470 in females at screening.

         12. Aspartate aminotransferase (AST) levels &gt;3 X the upper limit of normal, alanine
             aminotransferase (ALT) levels &gt;3 X the upper limit of normal, total bilirubin &gt;1.5 X
             the upper limit of normal, or creatinine &gt;1.5 X upper limit of normal on the Screening
             laboratory assessments, or other clinically significant laboratory abnormalities,
             which in the opinion of the Investigator may prevent the subject from safely
             participating in trial.

         13. Significant symptoms, medical conditions, or other circumstances which, in the opinion
             of the Investigator, would preclude compliance with the protocol, adequate cooperation
             in the trial or obtaining informed consent, or may prevent the subject from safely
             participating in trial (including, but not limited to, the risks described as
             precautions, warnings, and contraindications in the current version of the
             Investigator's Brochure for CAM2038).

         14. Is an employee of the Investigator or the trial site, with direct involvement in the
             proposed trial or other trials under the direction of the Investigator or trial site,
             or is a family member of an employee or of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Braeburn Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Braeburn Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkway Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haleyville Clinical Research LLC</name>
      <address>
        <city>Haleyville</city>
        <state>Alabama</state>
        <zip>35565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boyett Health Services Inc</name>
      <address>
        <city>Hamilton</city>
        <state>Alabama</state>
        <zip>35570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy East</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North County Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asclepes Research</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Practice</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergist Research</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Vijapura and Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Inc</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRY Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tellus Clinical Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Research Network of Kansas, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanley Street Treatment and Resources Inc</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novex Clinical Research</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PsychCare Consultants Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellness and Research Center</name>
      <address>
        <city>Belvidere</city>
        <state>New Jersey</state>
        <zip>07823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STARS/Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Star Medical Research</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivus Wellness &amp; Research Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frost Medical Group</name>
      <address>
        <city>Conshohocken</city>
        <state>Pennsylvania</state>
        <zip>19428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Pennsylvania Health System Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Research</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Trials, Inc</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Health Services</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <results_first_submitted>August 3, 2018</results_first_submitted>
  <results_first_submitted_qc>August 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2019</results_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02651584/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02651584/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: SL BPN Tablets + Placebo Subcutaneous (SC) Injections</title>
          <description>SL BPN: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
        </group>
        <group group_id="P2">
          <title>Group 2: CAM2038 SC Injections + SL Placebo Tablets</title>
          <description>CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 and 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all subjects who were randomized and receiving at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: SL BP/NX Tablets + Placebo SC Injections</title>
          <description>SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
        </group>
        <group group_id="B2">
          <title>Group 2: CAM2038 SC Injections + SL Placebo Tablets</title>
          <description>CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 and 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="215"/>
            <count group_id="B2" value="213"/>
            <count group_id="B3" value="428"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="10.89"/>
                    <measurement group_id="B2" value="38.7" spread="11.17"/>
                    <measurement group_id="B3" value="38.4" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="323"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="5.55"/>
                    <measurement group_id="B2" value="25.6" spread="5.03"/>
                    <measurement group_id="B3" value="25.9" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate, Denoted by Response Rate (Weeks 1-24).</title>
        <description>Response Rate, denoted by response rate (Weeks 1-24). A responder is defined as a subject with at least 33% of urine toxicology results collected during the Phase 1 (4 out of 12 urine samples) and 67% of urine toxicology results collected during Phase 2 (4 out of 6 urine samples) being negative for illicit opioids and self - reported illicit opioid use.</description>
        <time_frame>24 weeks</time_frame>
        <population>Includes all subjects who were randomized and receiving at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: SL BP/NX Tablets + Placebo SC Injections</title>
            <description>SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: CAM2038 SC Injections + SL Placebo Tablets</title>
            <description>CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 and 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate, Denoted by Response Rate (Weeks 1-24).</title>
          <description>Response Rate, denoted by response rate (Weeks 1-24). A responder is defined as a subject with at least 33% of urine toxicology results collected during the Phase 1 (4 out of 12 urine samples) and 67% of urine toxicology results collected during Phase 2 (4 out of 6 urine samples) being negative for illicit opioids and self - reported illicit opioid use.</description>
          <population>Includes all subjects who were randomized and receiving at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The p-value was based on the chi square test for non-inferiority with the margin of 10% point.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Distribution Function (CDF) of Percentage of Urine Samples Negative for Illicit Opioids</title>
        <description>Cumulative distribution function (CDF) of percentage of urine samples negative for illicit opioids comparing CAM2038 to SL BPN/NX as (supported by self-reported opioid use results)</description>
        <time_frame>24 weeks</time_frame>
        <population>Includes all subjects who were randomized and receiving at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SL BPN Tablets + Placebo Subcutaneous (SC) Injections</title>
            <description>SL BPN: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: CAM2038 SC Injections + SL Placebo Tablets</title>
            <description>CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 and 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Distribution Function (CDF) of Percentage of Urine Samples Negative for Illicit Opioids</title>
          <description>Cumulative distribution function (CDF) of percentage of urine samples negative for illicit opioids comparing CAM2038 to SL BPN/NX as (supported by self-reported opioid use results)</description>
          <population>Includes all subjects who were randomized and receiving at least one dose of study drug.</population>
          <units>percentage of negative urine samples</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Subjects' Self Reported Opioid Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="26.7" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Subjects' Self reported Opioid Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="26.7" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>including subject self-reported opioid use</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>not including self-reported opioid use</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Sustained Abstinence of Opioid Use</title>
        <description>Number of Subjects with Sustained Abstinence of Opioid Use taking SL BPN/NX and CAM2038</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: SL BPN/NX Tabs+ Placebo Subcutaneous (SC) Injections</title>
            <description>SL BPN: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: CAM2038 SC Injections + SL Placebo Tablets</title>
            <description>CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 and 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Sustained Abstinence of Opioid Use</title>
          <description>Number of Subjects with Sustained Abstinence of Opioid Use taking SL BPN/NX and CAM2038</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with sustained abstinence of opioids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects without sustained abstinence of opioids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Remaining in the Study (Retention Rate)</title>
        <description>Number of Subjects Remaining in the Study (Retention Rate) on SL BPN/NX and CAM2038</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: SL BPN/NX Tablets + Placebo SC Injections</title>
            <description>SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
          </group>
          <group group_id="O2">
            <title>Group 2: CAM2038 SC Injections + SL Placebo Tablets</title>
            <description>CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 and 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Remaining in the Study (Retention Rate)</title>
          <description>Number of Subjects Remaining in the Study (Retention Rate) on SL BPN/NX and CAM2038</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Retained</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Retained</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The p-value was based on the chi square test for non-inferiority with the margin of 15%.</non_inferiority_desc>
            <p_value>0.006</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>31 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: SL BPN/NX Tablets + Placebo SC Injections</title>
          <description>SL BPN: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).</description>
        </group>
        <group group_id="E2">
          <title>Group 2: CAM2038 SC Injections + SL Placebo Tablets</title>
          <description>CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 and 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Haemophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Acute Hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Localized infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Substance-induce mood disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="215"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="215"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sonnie Kim</name_or_title>
      <organization>Braeburn Pharmaceuticals</organization>
      <phone>1 610 467 8717</phone>
      <email>sonnie@braeburnrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

